NASDAQ · SYRE
Spyre Therapeutics, Inc.
$96.06-$2.90 (-2.93%)
Spyre Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.85% below the high.
Loading market information…
NASDAQ · ALVR · USD
Stock price, earnings
Quote as of Mar 18, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
AlloVir, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.38% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow AlloVir, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:20 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$96.06-$2.90 (-2.93%)
Spyre Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.85% below the high.
$1.48+$0.01 (+0.68%)
Achilles Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 1.99% below the high.
$0.68-$0.04 (-5.84%)
Rein Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.61% below the high.
$22.47-$0.59 (-2.56%)
Sigilon Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.75% below the high.
$0.88+$0.01 (+1.49%)
Kronos Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.73% below the high.
$4.97$0.00 (0.0%)
bluebird bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.62% below the high.
$0.30-$0.00 (-0.03%)
GreenLight Biosciences Holdings’s quoted price sits in the lower half of its reported 52-week range, 94.92% below the high.
$0.70-$0.06 (-7.74%)
Magenta Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.35% below the high.
